Drugs of Tomorrow 2001: Stable Angina providesin-depth analysis of compounds in late phasedevelopment for angina and an evaluation of the impactof these drugs on the market over the period to 2007.This report provides:• Evaluation of non-pharmacological treatment options• Thorough competitive evaluation of new compounds indevelopment for angina and their ability to satisfy theunmet needs that characterize the market• Identification of the opportunities that exist forcompanies to maximize the revenue potential of theirdevelopmental compounds in this market, includingsuggestions for licensing partners• Assessment of the impact of novel compounds on theanti-anginals that currently lead the market• Global sales forecasts for the anti-anginals that will belaunched over the period 2001-2007the market remains an attractive target for research anddevelopment. It is forecast to be worth more than $6.5billion by 2007.
